Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate

M. Diago; A. Olveira; R. Solá; M. Romero-Gómez; R. Moreno-Otero; R. Pérez; J. Salmerón; J. Enríquez; R. Planas; J. C. Gavilán; J. Del Olmo; R. Uribarrena; C. Sillero; A. Benítez; S. Sánchez-Galdón; B. Dalmau; L. Eraña; M. Montoro; J. Portu; J. M. Garijo; R. Barniol; A. Domínguez; R. Rota; J. L. Olcoz; M. Antón; X. Pamplona; T. Casanovas; E. Jiménez; M. Huarte; F. Díaz; J. Sánchez-Ruano; M. Orive; M. Muñoz-Sánchez; M. Roset

doi:10.1111/j.1365-2036.2007.03270.x

Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate

M. Diago^*, A. Olveira, R. Solá, M. Romero-Gómez, R. Moreno-Otero, R. Pérez, J. Salmerón, J. Enríquez, R. Planas, J. C. Gavilán, J. Del Olmo, R. Uribarrena, C. Sillero, A. Benítez, S. Sánchez-Galdón, B. Dalmau, L. Eraña, M. Montoro, J. Portu, J. M. GarijoR. Barniol, A. Domínguez, R. Rota, J. L. Olcoz, M. Antón, X. Pamplona, T. Casanovas, E. Jiménez, M. Huarte, F. Díaz, J. Sánchez-Ruano, M. Orive, M. Muñoz-Sánchez, M. Roset

^*Autor correspondiente de este trabajo

Departamento de Medicina

Producción científica: Contribución a una revista › Artículo › Investigación › revisión exhaustiva

15 Citas (Scopus)

Resumen

Background: Sustained virological response rates of up to 52% have been obtained with peginterferon α2a (40 kDa) plus ribavirin in patients suffering from chronic hepatitis C genotype 1 in randomized-controlled trials. Aim: To assess early virological response and its clinical utility in predicting an sustained virological response in patients suffering from chronic hepatitis C genotype 1 in routine clinical practice in Spain. Methods: Treatment-naïve patients received pegylated interferon α2a (40 kDa) 180 μg/week plus ribavirin 1000/1200 mg/day for 48 weeks, and were followed for a further 24 weeks. Overall, 475 patients received at least one dose of medication and were included in the efficacy population. Results: The overall sustained virological response rate was 48%. Of those with week 12 virological data, 83% had an early virological response. The negative predictive value of an early virological response was 93%. Conclusion: If sustained virological response is the goal, a treatment-decision based on a 12-week evaluation during routine clinical practice is feasible.

Idioma original	Inglés
Páginas (desde-hasta)	899-906
Número de páginas	8
Publicación	Alimentary Pharmacology and Therapeutics
Volumen	25
N.º	8
DOI	https://doi.org/10.1111/j.1365-2036.2007.03270.x
Estado	Publicada - abr 2007

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Acceder al documento

10.1111/j.1365-2036.2007.03270.x

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

Diago, M., Olveira, A., Solá, R., Romero-Gómez, M., Moreno-Otero, R., Pérez, R., Salmerón, J., Enríquez, J., Planas, R., Gavilán, J. C., Del Olmo, J., Uribarrena, R., Sillero, C., Benítez, A., Sánchez-Galdón, S., Dalmau, B., Eraña, L., Montoro, M., Portu, J., ... Roset, M. (2007). Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate. Alimentary Pharmacology and Therapeutics, 25(8), 899-906. https://doi.org/10.1111/j.1365-2036.2007.03270.x

@article{c700745882074264875e850fe854e487,

title = "Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate",

abstract = "Background: Sustained virological response rates of up to 52\% have been obtained with peginterferon α2a (40 kDa) plus ribavirin in patients suffering from chronic hepatitis C genotype 1 in randomized-controlled trials. Aim: To assess early virological response and its clinical utility in predicting an sustained virological response in patients suffering from chronic hepatitis C genotype 1 in routine clinical practice in Spain. Methods: Treatment-na{\"i}ve patients received pegylated interferon α2a (40 kDa) 180 μg/week plus ribavirin 1000/1200 mg/day for 48 weeks, and were followed for a further 24 weeks. Overall, 475 patients received at least one dose of medication and were included in the efficacy population. Results: The overall sustained virological response rate was 48\%. Of those with week 12 virological data, 83\% had an early virological response. The negative predictive value of an early virological response was 93\%. Conclusion: If sustained virological response is the goal, a treatment-decision based on a 12-week evaluation during routine clinical practice is feasible.",

author = "M. Diago and A. Olveira and R. Sol{\'a} and M. Romero-G{\'o}mez and R. Moreno-Otero and R. P{\'e}rez and J. Salmer{\'o}n and J. Enr{\'i}quez and R. Planas and Gavil{\'a}n, \{J. C.\} and \{Del Olmo\}, J. and R. Uribarrena and C. Sillero and A. Ben{\'i}tez and S. S{\'a}nchez-Gald{\'o}n and B. Dalmau and L. Era{\~n}a and M. Montoro and J. Portu and Garijo, \{J. M.\} and R. Barniol and A. Dom{\'i}nguez and R. Rota and Olcoz, \{J. L.\} and M. Ant{\'o}n and X. Pamplona and T. Casanovas and E. Jim{\'e}nez and M. Huarte and F. D{\'i}az and J. S{\'a}nchez-Ruano and M. Orive and M. Mu{\~n}oz-S{\'a}nchez and M. Roset",

year = "2007",

month = apr,

doi = "10.1111/j.1365-2036.2007.03270.x",

language = "English",

volume = "25",

pages = "899--906",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "John Wiley and Sons Inc.",

number = "8",

}

Diago, M, Olveira, A, Solá, R, Romero-Gómez, M, Moreno-Otero, R, Pérez, R, Salmerón, J, Enríquez, J, Planas, R, Gavilán, JC, Del Olmo, J, Uribarrena, R, Sillero, C, Benítez, A, Sánchez-Galdón, S, Dalmau, B, Eraña, L, Montoro, M, Portu, J, Garijo, JM, Barniol, R, Domínguez, A, Rota, R, Olcoz, JL, Antón, M, Pamplona, X, Casanovas, T, Jiménez, E, Huarte, M, Díaz, F, Sánchez-Ruano, J, Orive, M, Muñoz-Sánchez, M & Roset, M 2007, 'Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate', Alimentary Pharmacology and Therapeutics, vol. 25, n.º 8, pp. 899-906. https://doi.org/10.1111/j.1365-2036.2007.03270.x

Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate. / Diago, M.; Olveira, A.; Solá, R. et al.
En: Alimentary Pharmacology and Therapeutics, Vol. 25, N.º 8, 04.2007, p. 899-906.

Producción científica: Contribución a una revista › Artículo › Investigación › revisión exhaustiva

TY - JOUR

T1 - Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain

T2 - Early prediction of sustained virological response rate

AU - Diago, M.

AU - Olveira, A.

AU - Solá, R.

AU - Romero-Gómez, M.

AU - Moreno-Otero, R.

AU - Pérez, R.

AU - Salmerón, J.

AU - Enríquez, J.

AU - Planas, R.

AU - Gavilán, J. C.

AU - Del Olmo, J.

AU - Uribarrena, R.

AU - Sillero, C.

AU - Benítez, A.

AU - Sánchez-Galdón, S.

AU - Dalmau, B.

AU - Eraña, L.

AU - Montoro, M.

AU - Portu, J.

AU - Garijo, J. M.

AU - Barniol, R.

AU - Domínguez, A.

AU - Rota, R.

AU - Olcoz, J. L.

AU - Antón, M.

AU - Pamplona, X.

AU - Casanovas, T.

AU - Jiménez, E.

AU - Huarte, M.

AU - Díaz, F.

AU - Sánchez-Ruano, J.

AU - Orive, M.

AU - Muñoz-Sánchez, M.

AU - Roset, M.

PY - 2007/4

Y1 - 2007/4

N2 - Background: Sustained virological response rates of up to 52% have been obtained with peginterferon α2a (40 kDa) plus ribavirin in patients suffering from chronic hepatitis C genotype 1 in randomized-controlled trials. Aim: To assess early virological response and its clinical utility in predicting an sustained virological response in patients suffering from chronic hepatitis C genotype 1 in routine clinical practice in Spain. Methods: Treatment-naïve patients received pegylated interferon α2a (40 kDa) 180 μg/week plus ribavirin 1000/1200 mg/day for 48 weeks, and were followed for a further 24 weeks. Overall, 475 patients received at least one dose of medication and were included in the efficacy population. Results: The overall sustained virological response rate was 48%. Of those with week 12 virological data, 83% had an early virological response. The negative predictive value of an early virological response was 93%. Conclusion: If sustained virological response is the goal, a treatment-decision based on a 12-week evaluation during routine clinical practice is feasible.

AB - Background: Sustained virological response rates of up to 52% have been obtained with peginterferon α2a (40 kDa) plus ribavirin in patients suffering from chronic hepatitis C genotype 1 in randomized-controlled trials. Aim: To assess early virological response and its clinical utility in predicting an sustained virological response in patients suffering from chronic hepatitis C genotype 1 in routine clinical practice in Spain. Methods: Treatment-naïve patients received pegylated interferon α2a (40 kDa) 180 μg/week plus ribavirin 1000/1200 mg/day for 48 weeks, and were followed for a further 24 weeks. Overall, 475 patients received at least one dose of medication and were included in the efficacy population. Results: The overall sustained virological response rate was 48%. Of those with week 12 virological data, 83% had an early virological response. The negative predictive value of an early virological response was 93%. Conclusion: If sustained virological response is the goal, a treatment-decision based on a 12-week evaluation during routine clinical practice is feasible.

UR - https://www.scopus.com/pages/publications/34047137162

U2 - 10.1111/j.1365-2036.2007.03270.x

DO - 10.1111/j.1365-2036.2007.03270.x

M3 - Article

C2 - 17402993

AN - SCOPUS:34047137162

SN - 0269-2813

VL - 25

SP - 899

EP - 906

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 8

ER -

Diago M, Olveira A, Solá R, Romero-Gómez M, Moreno-Otero R, Pérez R et al. Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate. Alimentary Pharmacology and Therapeutics. 2007 abr;25(8):899-906. doi: 10.1111/j.1365-2036.2007.03270.x

Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate

Resumen

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto